Core One Labs Signs Letter of Intent with GMP Manufacturing Partner
23 Sep 2022 //
ACCESSWIRE
Core One Labs` Akome Move Psychedelic Drug Formulations to Next Stage of DevP
16 Sep 2022 //
ACCESSWIRE
Core One Labs` Scientists Successfully Complete Breakthrough in Producing API
02 Sep 2022 //
ACCESSWIRE
Core One Labs` Subsidiaries Successfully Produce Psilocin for to Psilocybin
12 Aug 2022 //
ACCESSWIRE
Core One Labs Upgrades to OTCQB Venture Market
06 Apr 2022 //
GLOBENEWSWIRE
Core One Labs Akome Receives Positive Results from Bioassay Studies
04 Apr 2022 //
GLOBENEWSWIRE
Core One Labs to Investigate Soliciting Investment
19 Mar 2022 //
GLOBENEWSWIRE
Vocan Bio, Awakened Bio Collaborate for Vocan`s Mass Production Capabilities
14 Mar 2022 //
GLOBENEWSWIRE
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
12 Mar 2022 //
GLOBENEWSWIRE
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic NMT
02 Mar 2022 //
GLOBENEWSWIRE
Core One Labs’ Files Milestone Patent for Recombinant Production System
21 Feb 2022 //
GLOBENEWSWIRE
Core One Labs Completes Strategic Acquisition of Awakened Biosciences
10 Feb 2022 //
GLOBENEWSWIRE
Akome Biotech Signs Research Agreement with University of Barcelona
26 Jan 2022 //
GLOBENEWSWIRE
Core One Labs Shows Proof of Concept and Files Patent for Psilocybin
21 Jan 2022 //
GLOBENEWSWIRE
Core One Labs Now Also Working to Biosynthesize DMT and Receives License
08 Jan 2022 //
GLOBENEWSWIRE
Core One Labs Submit Application for its Psilocybin Psychedelic-Assisted Therapy
13 Aug 2021 //
GLOBENEWS WIRE
Core One Labs is Nearing Production of Biosynthesized Psilocybin
05 Aug 2021 //
GLOBENEWSWIRE
Core One Labs’ Treatment of Parkinson’s Disease and Submits Application
26 Jul 2021 //
GLOBENEWSWIRE
Core One Labs Announces Details of Consolidation
16 Jul 2021 //
GLOBENEWSWIRE
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
14 Jun 2021 //
GLOBENEWSWIRE